

Anti-MerTK (Tyr749/753/754) Antibody

Our Anti-MerTK (Tyr749/753/754) rabbit polyclonal phosphospecific primary antibody from PhosphoSolut
Catalog # AN1451

Specification**Anti-MerTK (Tyr749/753/754) Antibody - Product Information**

Primary Accession	Q12866
Reactivity	Bovine
Host	Rabbit
Clonality	Polyclonal
Isotype	IgG
Calculated MW	110249

Anti-MerTK (Tyr749/753/754) Antibody - Additional Information

Gene ID **10461**

Other Names

c MER antibody, c mer proto oncogene tyrosine kinase antibody, c-mer antibody, cMER antibody, cmer protooncogene tyrosine kinase antibody, Eyk antibody, MER antibody, MER receptor tyrosine kinase antibody, MERK antibody, MERPEN antibody, MERTK antibody, MERTK c-mer proto-oncogene tyrosine kinase antibody, MERTK_HUMAN antibody, MGC133349 antibody, nmf12 antibody, Nyk antibody, Proto oncogene tyrosine protein kinase MER antibody, Proto oncogene tyrosine protein kinase MER precursor antibody, Proto-oncogene c-Mer antibody, Receptor tyrosine kinase MerTK antibody, RP38 antibody, STK kinase antibody, Tyrosine-protein kinase Mer antibody

Target/Specificity

Along with Tyro-3 and Axl, Mer is a member of the TAM family of receptor tyrosine kinases (RTKs). The TAM family of RTKs regulates cell proliferation/survival, cell adhesion and migration, and blood clot stabilization processes, along with the regulation of inflammatory cytokine release (Linger et al, 2008). Additionally, the TAM family has been linked to coagulopathy and cancer when altered experimentally or genetically (Linger et al, 2008). Tri-phosphorylation of MerTK at tyr749, tyr753 and tyr754 has been identified as a key target in platelet aggregation for developing a new anti-platelet drug that decreases bleeding complications, which are current side effects of similar drugs on the market today (Zhang et al, 2013). MerTK is also seen as a therapeutic target for treating lymphoblastic leukemias, melanoma, breast, lung, colon, liver, gastric, kidney, ovarian, uterine and brain cancers (Graham et al, 1994). There has recently been increased interest in synthesizing novel ATP-competitive small molecule tyrosine kinase inhibitors to decrease tri-phosphorylation of MerTK at tyr749, tyr753, and tyr754 as a therapeutic target to treat AML (Lee-Sherick et al, 2013).

Format

Antigen Affinity Purified from Pooled Serum

Storage

Maintain refrigerated at 2-8°C for up to 6 months. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.

Precautions

Anti-MerTK (Tyr749/753/754) Antibody is for research use only and not for use in diagnostic or

therapeutic procedures.


Shipping
Blue Ice

Anti-MerTK (Tyr749/753/754) Antibody - Protocols

Provided below are standard protocols that you may find useful for product applications.

- [Western Blot](#)
- [Blocking Peptides](#)
- [Dot Blot](#)
- [Immunohistochemistry](#)
- [Immunofluorescence](#)
- [Immunoprecipitation](#)
- [Flow Cytometry](#)
- [Cell Culture](#)

Anti-MerTK (Tyr749/753/754) Antibody - Images



Western blot of HEK293 lysate showing specific immunolabeling of the ~160 kDa MerTK phosphorylated at Tyr749/753/754 in the first lane (-). Phosphospecificity is shown in the second lane (+) where the immunolabeling is completely eliminated by blot treatment with lambda phosphatase (λ -Ptase, 1200 units for 60 minutes).

Anti-MerTK (Tyr749/753/754) Antibody - Background

Along with Tyro-3 and Axl, Mer is a member of the TAM family of receptor tyrosine kinases (RTKs). The TAM family of RTKs regulates cell proliferation/survival, cell adhesion and migration, and blood clot stabilization processes, along with the regulation of inflammatory cytokine release (Linger et al, 2008). Additionally, the TAM family has been linked to coagulopathy and cancer when altered experimentally or genetically (Linger et al, 2008). Tri-phosphorylation of MerTK at tyr749, tyr753 and tyr754 has been identified as a key target in platelet aggregation for developing a new anti-platelet drug that decreases bleeding complications, which are current side effects of similar drugs on the market today (Zhang et al, 2013). MerTK is also seen as a therapeutic target for treating lymphoblastic leukemias, melanoma, breast, lung, colon, liver, gastric, kidney, ovarian, uterine and brain cancers (Graham et al, 1994). There has recently been increased interest in synthesizing novel ATP-competitive small molecule tyrosine kinase inhibitors to decrease tri-phosphorylation of MerTK at tyr749, tyr753, and tyr754 as a therapeutic target to treat AML (Lee-Sherick et al, 2013).